Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions.
Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions.
复制标题
DOI：
10.3390/nu13113730
复制
发表时间：
2021-10-22
期刊：
影响因子：
5.9
通讯作者：
Sanft T
中科院分区：
文献类型：
--
作者：
Harrigan M;McGowan C;Hood A;Ferrucci LM;Nguyen T;Cartmel B;Li FY;Irwin ML;Sanft T
膳食补充剂的使用在一般人群中很常见，在癌症幸存者中更为普遍。世界癌症研究基金会/美国癌症研究所规定，膳食补充剂不应用于预防癌症。几种膳食补充剂具有潜在的药代动力学和药效学相互作用，可能会改变其临床疗效或增强乳腺癌治疗所用辅助内分泌治疗的不良反应。这项分析检查了自我报告的膳食补充剂使用的流行率以及在2010年至2017年期间进行的三项生活方式干预随机对照试验中招募的乳腺癌幸存者中与他莫昔芬和芳香酶抑制剂（AI）的潜在相互作用。使用天然药物数据库确定了他莫昔芬和AI的潜在相互作用。在475名乳腺癌幸存者中（诊断后2.9（平均）或2.5（标准差）年），393（83%）人报告使用膳食补充剂。共报告了108种不同类型的膳食补充剂，并确定了36种与他莫昔芬或AI的潜在不良相互作用。在353名服用他莫昔芬或AI的女性中，38%的人服用具有潜在相互作用风险的膳食补充剂。我们观察到乳腺癌幸存者中膳食补充剂的使用率很高，处方内分泌治疗和膳食补充剂之间存在不良相互作用的可能性很常见。
The use of dietary supplements is common in the general population and even more prevalent among cancer survivors. The World Cancer Research Fund/American Institute for Cancer Research specifies that dietary supplements should not be used for cancer prevention. Several dietary supplements have potential pharmacokinetic and pharmacodynamic interactions that may change their clinical efficacy or potentiate adverse effects of the adjuvant endocrine therapy prescribed for breast cancer treatment. This analysis examined the prevalence of self-reported dietary supplement use and the potential interactions with tamoxifen and aromatase inhibitors (AIs) among breast cancer survivors enrolled in three randomized controlled trials of lifestyle interventions conducted between 2010 and 2017. The potential interactions with tamoxifen and AIs were identified using the Natural Medicine Database. Among 475 breast cancer survivors (2.9 (mean) or 2.5 (standard deviation) years from diagnosis), 393 (83%) reported using dietary supplements. A total of 108 different types of dietary supplements were reported and 36 potential adverse interactions with tamoxifen or AIs were identified. Among the 353 women taking tamoxifen or AIs, 38% were taking dietary supplements with a potential risk of interactions. We observed a high prevalence of dietary supplement use among breast cancer survivors and the potential for adverse interactions between the prescribed endocrine therapy and dietary supplements was common.
登录
查看更多内容
DOI：
10.1080/10408398.2015.1126547
发表时间：
2017-11-02
影响因子：
10.2
作者：
Paterni I;Granchi C;Minutolo F
通讯作者：
Minutolo F
影响因子：
3.8
作者：
Sanft, Tara;Usiskin, Ilana;Irwin, Melinda L.
通讯作者：
Irwin, Melinda L.
影响因子：
6.2
作者：
Greenlee, Heather;Gammon, Marilie D.;Jacobson, Judith S.
通讯作者：
Jacobson, Judith S.
影响因子：
45.3
作者：
Irwin, Melinda L.;Cartmel, Brenda;Ligibel, Jennifer
通讯作者：
Ligibel, Jennifer
影响因子：
4.2
作者：
Bailey, Regan L.;Gahche, Jaime J.;Picciano, Mary Frances
通讯作者：
Picciano, Mary Frances